MagnetOs Bone Grafts Approved in Australia

Kuros Biosciences’ MagnetOs Granules and MagnetOs Putty have been entered on the Australian Register of Therapeutic Goods, enabling marketing and sales in the region. Surgical Specialties, Kuros’ Australian distributor, expects to launch products in 1Q21.

Over 2,000 patients have been treated worldwide since MagnetOs launched in the U.K. in 2017.

Data demonstrate equivalence of MagnetOs to the current gold standard, autograft, with over three years of clinical experience since its first use.

Joost de Bruijn, Chief Executive Officer of Kuros, said, “We are delighted that MagnetOs has achieved regulatory approval in Australia and that we will soon be able to add MagnetOs to the bone grafting options of clinicians and patients in Australia. We would also like to thank Surgical Specialties, our partner in Australia, for their work enabling this approval.”